1887

Abstract

Neuraminidase inhibitors are a cornerstone of influenza pandemic preparedness before vaccines can be mass-produced and thus a neuraminidase inhibitor-resistant pandemic is a serious threat to public health. Earlier work has demonstrated the potential for development and persistence of oseltamivir resistance in influenza A viruses exposed to environmentally relevant water concentrations of the drug when infecting mallards, the natural influenza reservoir that serves as the genetic base for human pandemics. As zanamivir is the major second-line neuraminidase inhibitor treatment, this study aimed to assess the potential for development and persistence of zanamivir resistance in an in vivo mallard model; especially important as zanamivir will probably be increasingly used. Our results indicate less potential for development and persistence of resistance due to zanamivir than oseltamivir in an environmental setting. This conclusion is based on: (1) the lower increase in zanamivir IC50 conferred by the mutations caused by zanamivir exposure (2–17-fold); (2) the higher zanamivir water concentration needed to induce resistance (at least 10 µg l); (3) the lack of zanamivir resistance persistence without drug pressure; and (4) the multiple resistance-related substitutions seen during zanamivir exposure (V116A, A138V, R152K, T157I and D199G) suggesting lack of one straight-forward evolutionary path to resistance. Our study also adds further evidence regarding the stability of the oseltamivir-induced substitution H275Y without drug pressure, and demonstrates the ability of a H275Y-carrying virus to acquire secondary mutations, further boosting oseltamivir resistance when exposed to zanamivir. Similar studies using influenza A viruses of the N2-phylogenetic group of neuraminidases are recommended.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000977
2017-11-15
2019-09-18
Loading full text...

Full text loading...

/deliver/fulltext/jgv/98/12/2937.html?itemId=/content/journal/jgv/10.1099/jgv.0.000977&mimeType=html&fmt=ahah

References

  1. Johnson NP, Mueller J. Updating the accounts: global mortality of the 1918–1920 "Spanish" influenza pandemic. Bull Hist Med 2002; 76: 105– 115 [CrossRef] [PubMed]
    [Google Scholar]
  2. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12: 687– 695 [CrossRef] [PubMed]
    [Google Scholar]
  3. Olsen B, Munster VJ, Wallensten A, Waldenström J, Osterhaus AD et al. Global patterns of influenza a virus in wild birds. Science 2006; 312: 384– 388 [CrossRef] [PubMed]
    [Google Scholar]
  4. Worobey M, Han GZ, Rambaut A. A synchronized global sweep of the internal genes of modern avian influenza virus. Nature 2014; 508: 254– 257 [CrossRef] [PubMed]
    [Google Scholar]
  5. Kuiken T. Is low pathogenic avian influenza virus virulent for wild waterbirds?. Proc Biol Sci 2013; 280: 20130990 [CrossRef] [PubMed]
    [Google Scholar]
  6. Alexander DJ, Brown IH. History of highly pathogenic avian influenza. Rev Sci Tech 2009; 28: 19– 38 [CrossRef] [PubMed]
    [Google Scholar]
  7. Tanner WD, Toth DJ, Gundlapalli AV. The pandemic potential of avian influenza A(H7N9) virus: a review. Epidemiol Infect 2015; 143: 3359– 3374 [CrossRef] [PubMed]
    [Google Scholar]
  8. World Health Organization (WHO) 2017; Influenza at the human-animal interface. Summary and assessment, 17 January to 14 February 2017 www.who.int/entity/influenza/human_animal_interface/HAI_Risk_Assessment/en/index.html (accessed 3 October 2017
  9. Cox NJ, Subbarao K. Global epidemiology of influenza: past and present. Annu Rev Med 2000; 51: 407– 421 [CrossRef] [PubMed]
    [Google Scholar]
  10. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. Evolution and ecology of influenza A viruses. Microbiol Rev 1992; 56: 152– 179 [PubMed]
    [Google Scholar]
  11. Guan Y, Vijaykrishna D, Bahl J, Zhu H, Wang J et al. The emergence of pandemic influenza viruses. Protein Cell 2010; 1: 9– 13 [CrossRef] [PubMed]
    [Google Scholar]
  12. Ison MG, Hay A. Antivirals: targets and use. In Webster RG, Monto AS, Braciale TJ, Lamb RA. (editors) Textbook of Influenza, 2nd ed. Hoboken, NJ: Wiley; 2013; pp. 392– 418 [Crossref]
    [Google Scholar]
  13. GlaxoSmithKline A study of intravenous zanamivir in the treatment of hospitalized patients with Influenza infection (NCT01527110). https://clinicaltrials.gov/ct2/show/NCT01527110 (accessed 3 October 2017)
  14. GlaxoSmithKline 2017; A study of intravenous zanamivir versus oral oseltamivir in adults and adolecents hospitalized with Influenza (ZORO) (NCT01231620). http://clinicaltrials.gov/ct2/show/NCT01231620 accessed October 3, 2017
  15. Hurt AC, Selleck P, Komadina N, Shaw R, Brown L et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007; 73: 228– 231 [CrossRef] [PubMed]
    [Google Scholar]
  16. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360: 953– 956 [CrossRef] [PubMed]
    [Google Scholar]
  17. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009; 14: [CrossRef] [PubMed]
    [Google Scholar]
  18. Duan S, Govorkova EA, Bahl J, Zaraket H, Baranovich T et al. Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat Commun 2014; 5: 5029 [CrossRef] [PubMed]
    [Google Scholar]
  19. Hurt AC, Holien JK, Barr IG. In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother 2009; 53: 4433– 4440 [CrossRef] [PubMed]
    [Google Scholar]
  20. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009; 83: 10366– 10373 [CrossRef] [PubMed]
    [Google Scholar]
  21. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385– 3390 [PubMed]
    [Google Scholar]
  22. Lindberg RH, Fedorova G, Blum KM, Pulit-Prociak J, Gillman A et al. Online solid phase extraction liquid chromatography using bonded zwitterionic stationary phases and tandem mass spectrometry for rapid environmental trace analysis of highly polar hydrophilic compounds – Application for the antiviral drug Zanamivir. Talanta 2015; 141: 164– 169 [CrossRef] [PubMed]
    [Google Scholar]
  23. Accinelli C, Saccà ML, Fick J, Mencarelli M, Lindberg R et al. Dissipation and removal of oseltamivir (Tamiflu) in different aquatic environments. Chemosphere 2010; 79: 891– 897 [CrossRef] [PubMed]
    [Google Scholar]
  24. Gonçalves C, Pérez S, Osorio V, Petrovic M, Alpendurada MF et al. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol 2011; 45: 4307– 4314 [CrossRef] [PubMed]
    [Google Scholar]
  25. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Detection of antiviral drugs oseltamivir phosphate and oseltamivir carboxylate in Neya River, Osaka, Japan. J Water Environ Technol 2010; 8: 363– 372 [CrossRef]
    [Google Scholar]
  26. Takanami R, Ozaki H, Giri RR, Taniguchi S, Hayashi S. Antiviral drugs zanamivir and oseltamivir found in wastewater and surface water in Osaka, Japan. J Water Environ Technol 2012; 10: 57– 68 [CrossRef]
    [Google Scholar]
  27. Järhult JD. Oseltamivir (Tamiflu®) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmission of an oseltamivir-resistant virus to humans – a review. Infect Ecol Epidemiol 2012; 2: 18385 [CrossRef] [PubMed]
    [Google Scholar]
  28. Järhult JD, Muradrasoli S, Wahlgren J, Söderström H, Orozovic G et al. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One 2011; 6: e24742 [CrossRef] [PubMed]
    [Google Scholar]
  29. Gillman A, Muradrasoli S, Söderström H, Holmberg F, Latorre-Margalef N et al. Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards. Appl Environ Microbiol 2015; 81: 2378– 2383 [CrossRef] [PubMed]
    [Google Scholar]
  30. Achenbach JE, Bowen RA. Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in mallard ducks. Antimicrob Agents Chemother 2013; 57: 2171– 2181 [CrossRef] [PubMed]
    [Google Scholar]
  31. Gillman A, Nykvist M, Muradrasoli S, Söderström H, Wille M et al. Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. Antimicrob Agents Chemother 2015; 59: 5196– 5202 [CrossRef] [PubMed]
    [Google Scholar]
  32. Gillman A, Muradrasoli S, Söderström H, Nordh J, Bröjer C et al. Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir. PLoS One 2013; 8: e71230 [CrossRef] [PubMed]
    [Google Scholar]
  33. Gillman A, Muradrasoli S, Mårdnäs A, Söderström H, Fedorova G et al. Oseltamivir resistance in influenza A(H6N2) caused by an R292K substitution in neuraminidase is not maintained in mallards without drug pressure. PLoS One 2015; 10: e0139415 [CrossRef] [PubMed]
    [Google Scholar]
  34. Boivin G, Goyette N, Hardy I, Aoki F, Wagner A et al. Rapid antiviral effect of inhaled zanamivir in the treatment of naturally occurring influenza in otherwise healthy adults. J Infect Dis 2000; 181: 1471– 1474 [CrossRef] [PubMed]
    [Google Scholar]
  35. Hedrick JA, Barzilai A, Behre U, Henderson FW, Hammond J et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000; 19: 410– 417 [CrossRef] [PubMed]
    [Google Scholar]
  36. Ambrozaitis A, Gravenstein S, van Essen GA, Rubinstein E, Balciuniene L et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc 2005; 6: 367– 374 [CrossRef] [PubMed]
    [Google Scholar]
  37. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family study group. N Engl J Med 2000; 343: 1282– 1289 [CrossRef] [PubMed]
    [Google Scholar]
  38. McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 2013; 7: 25– 36 [CrossRef] [PubMed]
    [Google Scholar]
  39. Samson M, Pizzorno A, Abed Y, Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98: 174– 185 [CrossRef] [PubMed]
    [Google Scholar]
  40. Baz M, Abed Y, Boivin G. Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir. Antiviral Res 2007; 74: 159– 162 [CrossRef] [PubMed]
    [Google Scholar]
  41. McKimm-Breschkin JL, Rootes C, Mohr PG, Barrett S, Streltsov VA. In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. J Antimicrob Chemother 2012; 67: 1874– 1883 [CrossRef] [PubMed]
    [Google Scholar]
  42. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012 Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. Wkly Epidemiol Rec 2012; 87: 369– 374
    [Google Scholar]
  43. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP et al. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006; 443: 45– 49 [CrossRef] [PubMed]
    [Google Scholar]
  44. Orozovic G, Orozovic K, Lennerstrand J, Olsen B. Detection of resistance mutations to antivirals oseltamivir and zanamivir in avian influenza A viruses isolated from wild birds. PLoS One 2011; 6: e16028 [CrossRef] [PubMed]
    [Google Scholar]
  45. Boltz DA, Douangngeun B, Phommachanh P, Sinthasak S, Mondry R et al. Emergence of H5N1 avian influenza viruses with reduced sensitivity to neuraminidase inhibitors and novel reassortants in Lao people's democratic republic. J Gen Virol 2010; 91: 949– 959 [CrossRef] [PubMed]
    [Google Scholar]
  46. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog 2010; 6: e1000933 [CrossRef] [PubMed]
    [Google Scholar]
  47. Abed Y, Nehmé B, Baz M, Boivin G. Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes. Antiviral Res 2008; 77: 163– 166 [CrossRef] [PubMed]
    [Google Scholar]
  48. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983; 303: 41– 44 [CrossRef] [PubMed]
    [Google Scholar]
  49. Tran DN, Pham TM, Ha MT, Hayakawa S, Mizuguchi M et al. Molecular epidemiology of influenza A virus infection among hospitalized children in Vietnam during post-pandemic period. J Med Virol 2015; 87: 904– 912 [CrossRef] [PubMed]
    [Google Scholar]
  50. Ghedin E, Laplante J, Depasse J, Wentworth DE, Santos RP et al. Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance. J Infect Dis 2011; 203: 168– 174 [CrossRef] [PubMed]
    [Google Scholar]
  51. Hurt AC, Iannello P, Jachno K, Komadina N, Hampson AW et al. Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient. Antimicrob Agents Chemother 2006; 50: 1872– 1874 [CrossRef] [PubMed]
    [Google Scholar]
  52. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res 2004; 103: 199– 203 [CrossRef] [PubMed]
    [Google Scholar]
  53. Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X et al. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses 2013; 7: 645– 658 [CrossRef] [PubMed]
    [Google Scholar]
  54. Takashita E, Meijer A, Lackenby A, Gubareva L, Rebelo-de-Andrade H et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014. Antiviral Res 2015; 117: 27– 38 [CrossRef] [PubMed]
    [Google Scholar]
  55. Meijer A, Rebelo-de-Andrade H, Correia V, Besselaar T, Drager-Dayal R et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. Antiviral Res 2014; 110: 31– 41 [CrossRef] [PubMed]
    [Google Scholar]
  56. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49: 4515– 4520 [CrossRef] [PubMed]
    [Google Scholar]
  57. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 2001; 45: 3403– 3408 [CrossRef] [PubMed]
    [Google Scholar]
  58. Baek YH, Song MS, Lee EY, Kim YI, Kim EH et al. Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors. J Virol 2015; 89: 287– 299 [CrossRef] [PubMed]
    [Google Scholar]
  59. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS et al. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 2006; 80: 8787– 8795 [CrossRef] [PubMed]
    [Google Scholar]
  60. Pan D, Sun H, Bai C, Shen Y, Jin N et al. Prediction of zanamivir efficiency over the possible 2009 influenza A (H1N1) mutants by multiple molecular dynamics simulations and free energy calculations. J Mol Model 2011; 17: 2465– 2473 [CrossRef] [PubMed]
    [Google Scholar]
  61. Spackman E, Suarez DL. Type A influenza virus detection and quantitation by real-time RT-PCR. Methods Mol Biol 2008; 436: 19– 26 [CrossRef] [PubMed]
    [Google Scholar]
  62. Lackenby A. 2008; Determination of influenza virus susceptibility to neuraminidase inhibitors using a fluorescent substrate. International society for influenza and other respiratory virus diseases. www.nisn.org/documents/Zambon_-_VIRGIL_IC50_SOP.pdf (accessed 3 October 2017)
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000977
Loading
/content/journal/jgv/10.1099/jgv.0.000977
Loading

Data & Media loading...

Supplementary File 1

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error